Dalbavancin use in an academic medical center and associated cost-savings.
Int J Antimicrob Agents. 2019 Aug 06;:
Authors: Streifel AC, Sikka MK, Bowen CD, Lewis JS
Dalbavancin is a lipoglycopeptide antibiotic active against gram positive organisms with unique weekly dosing. This retrospective study included 37 patients receiving an average of 2.7 weeks of dalbavancin. 9 (24%) patients were readmitted to the hospital within 30 days. A total of 617 hospital days were saved, estimated to be $1,495,336 in savings and a mean cost avoidance of $40,414 per patient. Dalbavancin provides a valuable antibiotic option that may minimize health care expenditures.
PMID: 31398481 [PubMed - as supplied by publisher]